ERBB2 and non-small cell lung carcinoma: In the context of NSCLC, several other targetable driver oncogenes have been identified, including serine/threonine-protein kinase b-raf (BRAF; 3–8%), Kirsten rat sarcoma viral oncogene homolog (KRAS; 20–30%), hepatocyte growth factor receptor (MET; 3%), human epidermal growth factor receptor 2 (HER2; 2%), anaplastic lymphoma kinase (ALK; 1–7%), ROS1 proto-oncogene receptor tyrosine kinase (ROS1; 1–2%), tropomyosin receptor kinase (NTRK; <1%), rearranged during transfection (RET; 1–2%), and neuregulin 1 (NRG1) fusion variants (0,14%) [9,10,11,12,13,14,15].